Cablivi gets FDA OK for blood clotting disorder
The US Food and Drug Administration (FDA) has approved Sanofi’s Cablivi as the first treatment for adult patients with a rare blood clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP).
Read More
